Simon Latimer | Head, IR |
John Higgins | CEO |
Matthew Korenberg | President & CFO |
Octavio Espinoza | CFO |
Joseph Pantginis | HC Wainwright |
Larry Solow | CJS Securities |
Matthew Hewitt | Craig-Hallum Capital Group |
Scott Henry | ROTH Capital |
Good afternoon. My name is Vinesin, and I will be your conference actor today. At this time, I would like to welcome everyone to the Ligand Pharmaceuticals Third Quarter 2022 Earnings Conference Call. [Operator Instructions] I would now like to turn the conference over to Simon Latimer, Head of Investor Relations. Please go ahead.